

CRYSTALLINE COMPOUND OR BASIC SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF

TECHNICAL FIELD

5 The present invention belongs to the field of drug development and particularly relates to a crystalline PD-1/PD-L1 inhibitor compound or basic salt, preparation method therefor and use thereof.

BACKGROUND

10 The immune system plays a very important role in controlling and eliminating diseases, such as cancer. However, tumor cells are often able to develop a strategy for escaping or suppressing the monitoring of the immune system to promote their malignant growth. One very important mechanism is to change the expression of co-stimulatory and co-inhibitory immune checkpoint molecules on immunocytes. Blocking the signal
15 pathway of immune checkpoint molecules, such as PD-1, has been shown to be an extremely promising and effective therapeutic means.

 Programmed cell death protein 1 (PD-1), also known as CD279, is a receptor expressed on the surfaces of activated T cells, natural killer T cells, B cells and macrophages. Its structure contains an extracellular domain similar to an immunoglobulin
20 variable region, a transmembrane domain and an intracellular domain, where the intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine kinase-based inhibitory domain and an immunoreceptor tyrosine kinase-based transduction domain, suggesting that PD-1 can down-regulate T cell receptor-mediated signal pathways.

25 PD-1 has two ligands: PD-L1 and PD-L2, and they are different in their expression profile. The expression of PD-L1 will be up-regulated in macrophages and dendritic cells after treatment with lipopolysaccharide (LPS) and granulocyte-macrophage colony-stimulating factor (GM-CSF), and will also be up-regulated in T cells and B cells after stimulation of T cell receptor and B cell receptor signal pathways. PD-L1 is also highly
30 expressed in almost all tumor cells, and the expression will be up-regulated after stimulation of interferon (IFN) gamma. As a matter of fact, the expression of PD-L1 in a variety of tumors is considered to have prognostic relevance; in contrast, the expression of PD-L2 is relatively concentrated, mainly on dendritic cells.


 When T cells expressing PD-1 come into contact with cells expressing the ligands
35 of PD-1, those antigen-stimulated functional activities, such as cell proliferation, cytokine release and cell lysis activity, are all inhibited. Therefore, the interaction between PD-1 and ligands thereof can function as an intrinsic negative feedback regulation mechanism to prevent T cell hyperactivation during infection, immune tolerance or tumorigenesis, thus reducing the occurrence of autoimmune diseases and promoting self-tolerance.
40 Long-term antigenic stimulation, e.g., in tumor or long-term infection, can cause T cells to express high levels of PD-1 and make them inactive and nonfunctional in these long-

term reactions with antigens, which is also referred to as T cell exhaustion. For B cells, there are also inhibitory effects caused by PD-1 and its ligands and corresponding functional exhaustion.

Some evidence from preclinical animal studies indicates that PD-1 and ligands thereof can down-regulate the immunoreaction. PD-1-deficient mice will develop lupus erythematosus-like acute proliferative glomerulonephritis and dilated cardiomyopathy. Utilizing the antibody of PD-L1 to block PD-1/PD-L1 interaction has been shown to be able to restore and enhance T cell activation in many systems. The monoclonal antibody of PD-L1 can also benefit patients with advanced cancers. In some preclinical animal tumor models, it was also shown that blocking the signal pathway of PD-1/PD-L1 with a monoclonal antibody can enhance immunoreaction and lead to immunoreactions to a series of histologically significantly different tumors. With the long-term infection LCMV model, the interaction between PD-1 and PD-L1 has been found to be able to inhibit the activation and proliferation of virus-specific CD8 T cells and the acquisition of effector cell functions. Besides being capable of enhancing the immunoreaction to long-term antigens, blocking the pathway of PD-1/PD-L1 was also discovered to be able to enhance response to vaccines, including response to a therapeutic vaccine in long-term infection.

These results indicate that small-molecule inhibitors that target and block the PD-1/PD-L1 interaction can be an effective therapeutic means for blocking the PD-1/PD-L1-mediated inhibitory signal pathway to enhance or restore the function of T cells, and will have very good efficacy in immunotherapy for a variety of cancers and other immunity-related diseases.

During long-term research, Abbisko Therapeutics Co., Ltd. found a small-molecule compound having the effect of inhibiting PD-1/PD-L1 (WO2019149183A1, international publication date: August 8, 2019), a representative compound of which is shown below:



The name of the compound is (2*S*,2'*S*)-1,1'-((((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(4-cyclopropylpyridine-6,3-diyl))bis(methylene))bis(piperidine-2-carboxylic acid) (the compound of formula (I)). The compound has a strong inhibitory effect on the protein interaction of PD-1/PD-L1, and the inhibitory effect can enhance or restore the activation of T cells at the cellular level. The compound can satisfy the requirements of target and immune therapy for tumors, immunity-related diseases and disorders, communicable diseases, infectious diseases or metabolic diseases, etc., at this stage in China and other countries.


During later pharmaceutical research, it was found that the compound of formula (I)

reported in WO2019149183A1 is a trifluoroacetate freeze-dried amorphous compound that has poor solid-state properties, is very hygroscopic, has poor solubility and is not suitable for clinical formulation development. Therefore, in order to satisfy the needs of clinical research and the launch of drug formulations, there is an urgent need to develop an aggregate form suitable for drug development to overcome the defects in the prior art.

SUMMARY

To solve the problems in the prior art, the inventors intensively studied different aggregate forms of the compound of formula (I) and developed several crystalline free forms of the compound or basic salts thereof through a large number of salt form and crystalline form screening experiments. The crystalline free forms of the compound greatly improve physicochemical properties, such as hygroscopicity, solubility and physicochemical stability, of the compound of formula (I), and the crystalline basic salts of the compound greatly improve physicochemical properties such as solubility and physicochemical stability. The crystalline free forms of the compound or the basic salts thereof have improved bioavailability, meet the requirements for industrial production and can satisfy the need to develop clinical pharmaceutical formulations. The crystalline forms of the compound or the basic salts thereof have very important clinical application value and are expected to be developed into new-generation PD-1/PD-L1 small-molecule inhibitors soon.

A first aspect of the present invention provides a crystalline basic salt of a compound of formula (I):



wherein the basic salt is selected from the group consisting of lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt and ammonium salt.

As a preferred embodiment, the crystalline basic salt of the compound of formula (I) is a sodium salt.

As a further preferred embodiment, each molecule of the crystalline sodium salt of the compound of formula (I) comprises the compound of formula (I) in free form and the sodium atom in a molar ratio of 1:1 or 1:2, wherein the sodium salt is referred to as a monosodium salt when the molar ratio is 1:1, and the sodium salt is referred to as a disodium salt when the molar ratio is 1:2.

As a more further preferred embodiment, each molecule of the crystalline sodium salt of the compound of formula (I) comprises the compound of formula (I) in free form and the sodium atom in a molar ratio of 1:2.

As a preferred embodiment, the crystalline sodium salt of the compound of formula

(I) is an anhydrate or a hydrate.

As a further preferred embodiment, each molecule of the crystalline sodium salt hydrate of the compound of formula (I) comprises the compound of formula (I) in free form and the water molecule in a molar ratio of 1.0:(0.1-10.0), wherein the hydrate is referred to as a hemihydrate when the molar ratio is 1.0:0.5, the hydrate is referred to as a monohydrate when the molar ratio is 1.0:1.0, and the hydrate is referred to as a dihydrate when the molar ratio is 1.0:2.0; and following this pattern, subsequent ratios are termed trihydrate, tetrahydrate, pentahydrate, and so on.

As a more further preferred embodiment, each molecule of the crystalline sodium salt hydrate of the compound of formula (I) comprises the compound of formula (I) in free form and the water molecule in a molar ratio of 1.0:(1.0-5.0).

As a more further preferred embodiment, each molecule of the crystalline sodium salt hydrate of the compound of formula (I) comprises the compound of formula (I) in free form and the water molecule in a molar ratio of 1.0:4.0 or 1.0:2.0.

As a more further preferred embodiment, the crystalline basic salt of the compound of formula (I) is a crystalline form A of disodium salt hydrate having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of $8.60\pm 0.2^\circ$, $9.97\pm 0.2^\circ$, $12.92\pm 0.2^\circ$, $15.03\pm 0.2^\circ$, $17.62\pm 0.2^\circ$, $17.93\pm 0.2^\circ$, $20.04\pm 0.2^\circ$, $22.07\pm 0.2^\circ$, $23.18\pm 0.2^\circ$, $23.60\pm 0.2^\circ$ and $27.06\pm 0.2^\circ$.

As the most preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form A of disodium salt hydrate comprises peaks substantially identical ($\pm 0.2^\circ$) to those at angles of diffraction (2θ) shown in FIG. 1, and X-ray powder diffraction data thereof are shown in Table 1:

Table 1

$2\theta (^\circ)$	Intensity%	$2\theta (^\circ)$	Intensity%
8.60	100.0%	24.35	4.0%
9.38	1.3%	25.77	2.6%
9.97	6.9%	26.08	2.8%
11.76	0.7%	27.06	6.8%
12.92	11.1%	27.40	2.1%
15.03	7.5%	28.20	1.6%
15.49	1.2%	28.46	2.8%
16.01	2.7%	28.80	1.3%
17.62	17.6%	30.32	3.0%
17.93	15.5%	30.81	1.5%
18.78	1.7%	32.78	0.6%
19.83	5.0%	33.85	1.2%
20.04	11.9%	35.80	1.3%
20.46	5.9%	37.68	0.4%
21.24	1.3%	38.21	1.1%
22.07	8.9%	38.82	0.3%
22.64	0.4%	39.88	1.3%
23.18	7.2%	40.78	0.5%

23.60	7.0%	43.21	0.3%
24.02	1.0%	44.24	0.5%

The crystalline form is designated crystalline form A of disodium salt hydrate.

As the most preferred embodiment, the crystalline basic salt of the compound of formula (I) is a crystalline form A of disodium salt hydrate, wherein a unit cell of the crystalline form A of disodium salt hydrate is a monoclinic crystal system with the following unit cell parameters: $a = 20.00(5) \text{ \AA}$, $b = 5.798(16) \text{ \AA}$, $c = 20.44(11) \text{ \AA}$, $\alpha = 90^\circ$, $\beta = 94.8(2)^\circ$, $\gamma = 90^\circ$ and a unit cell volume V of $2362(15) \text{ \AA}^3$. Z' is 0.5, and an asymmetric unit consists of 0.5 API anions, 1 sodium ion and 2 water molecules. The structure of a unit cell of a single crystal thereof is shown in FIG. 7.

As the most preferred embodiment, the crystalline basic salt of the compound of formula (I) is a crystalline form A of disodium salt hydrate having DSC/TGA graphs that are substantially those shown in FIG. 8.

As a more further preferred embodiment, the crystalline basic salt of the compound of formula (I) is a crystalline form B of disodium salt anhydrate having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of $6.60 \pm 0.2^\circ$, $7.46 \pm 0.2^\circ$, $12.43 \pm 0.2^\circ$, $13.32 \pm 0.2^\circ$, $13.63 \pm 0.2^\circ$, $15.54 \pm 0.2^\circ$, $17.32 \pm 0.2^\circ$, $18.68 \pm 0.2^\circ$ and $21.73 \pm 0.2^\circ$.

As the most preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form B of disodium salt anhydrate comprises peaks substantially identical ($\pm 0.2^\circ$) to those at angles of diffraction (2θ) shown in FIG. 2, and X-ray powder diffraction data thereof are shown in Table 2:

Table 2

$2\theta (^\circ)$	Intensity%	$2\theta (^\circ)$	Intensity%
6.60	100.0%	18.41	6.8%
7.46	89.9%	18.68	8.4%
11.16	4.1%	20.51	3.1%
12.43	23.3%	21.73	13.7%
13.32	58.0%	23.57	3.5%
13.63	10.3%	27.26	5.6%
14.99	4.8%	28.64	2.1%
15.54	13.3%	31.83°	2.6%
17.32	66.6%	37.82	1.9%

The crystalline form is designated crystalline form B of disodium salt anhydrate and has a melting point of 316.4°C .

As the most preferred embodiment, the crystalline basic salt of the compound of formula (I) is a crystalline form B of disodium salt anhydrate having DSC/TGA graphs that are substantially those shown in FIG. 9.

A second aspect of the present invention provides a preparation method for the aforementioned crystalline basic salt of the compound of formula (I), comprising the

following steps:

- 1) dissolving or dispersing the compound of formula (I) in free form in water or a suitable organic solvent, and adding a basic solution to the above system; or adding the compound of formula (I) in free form to a basic solution; and
- 2) collecting a solid product precipitated during the above salt-forming reaction, or creating a degree of supersaturation in the salt-forming system to obtain a crystalline product;

wherein the basic salt is selected from the group consisting of lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt and ammonium salt.

As a preferred embodiment, the basic solution is selected from the group consisting of solutions of lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide and ammonia in water or in an organic solvent.

As a preferred embodiment, methods for creating the degree of supersaturation in the salt-forming system in step 2) of the preparation method include one or more of the following: adding a seed crystal, volatilizing the solvent, adding an anti-solvent and cooling.

As a preferred embodiment, the organic solvent during salt formation in step 1) of the preparation method is selected from the group consisting of alcohols, chloroalkanes, ketones, ethers, cyclic ethers, esters, alkanes, cycloalkanes, benzenes, amides and sulfoxides, and mixtures thereof and aqueous solutions thereof.


As a further preferred embodiment, the organic solvent during salt formation in step 1) of the preparation method is selected from the group consisting of methanol, ethanol, *n*-propanol, isopropanol, dichloromethane, heptane, acetonitrile, acetone, methyl ethyl ketone, toluene, 1,4-dioxane, tetrahydrofuran, *N,N*-dimethylformamide, ethyl acetate, isopropyl acetate, methyl *tert*-butyl ether and 2-methoxyethyl ether, and mixtures thereof and aqueous solutions thereof.

A third aspect of the present invention provides a preparation method for the aforementioned crystalline basic salt of the compound of formula (I), comprising the following step: transforming one crystalline form of the basic salt of the compound of formula (I) into another crystalline form of the salt by using a crystalline form transformation method, wherein the crystalline form transformation method includes heating or suspension crystalline form transformation in a solvent.

As a preferred embodiment, the solvent is selected from the group consisting of methanol, ethanol, *n*-propanol, isopropanol, dichloromethane, heptane, acetonitrile, acetone, methyl ethyl ketone, toluene, 1,4-dioxane, tetrahydrofuran, *N,N*-dimethylformamide, ethyl acetate, isopropyl acetate, methyl *tert*-butyl ether and 2-methoxyethyl ether, and mixtures thereof and aqueous solutions thereof.

A fourth aspect of the present invention provides a crystalline form of the compound

of formula (I) in free form:



As a preferred embodiment, the crystalline form of the compound of formula (I) in free form is crystalline form C, crystalline form D, crystalline form E or crystalline form F.

As a further preferred embodiment, the crystalline form of the compound of formula (I) in free form is a crystalline form C having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of $7.80 \pm 0.2^\circ$, $11.97 \pm 0.2^\circ$, $12.42 \pm 0.2^\circ$, $15.98 \pm 0.2^\circ$, $17.37 \pm 0.2^\circ$, $18.82 \pm 0.2^\circ$, $22.47 \pm 0.2^\circ$, $23.30 \pm 0.2^\circ$, $25.01 \pm 0.2^\circ$ and $25.63 \pm 0.2^\circ$.

As a more further preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form C comprises peaks substantially identical ($\pm 0.2^\circ$) to those at angles of diffraction (2θ) shown in FIG. 3, and X-ray powder diffraction data thereof are shown in Table 3:

Table 3

2θ (°)	Intensity%	2θ (°)	Intensity%
6.21	10.9%	24.35	3.6%
7.80	21.1%	25.01	15.6%
8.82	1.1%	25.63	25.5%
11.97	59.2%	26.48	2.6%
12.42	67.2%	27.48	1.3%
14.59	9.5%	28.41	4.7%
15.17	1.4%	28.58	2.4%
15.81	8.7%	29.38	2.9%
15.98	21.2%	30.09	2.0%
17.37	100.0%	31.47	6.3%
18.82	12.1%	33.05	1.1%
19.52	4.0%	35.36	1.9%
20.39	6.0%	38.00	1.0%
20.94	3.9%	38.63	1.8%
21.60	3.5%	39.90	1.0%
22.47	13.3%	42.72	0.8%
23.30	27.1%	43.95	0.7%
23.86	9.6%		

The crystalline form is designated free-form crystalline form C and has a melting point of 169.5 °C.

5 As the most preferred embodiment, the crystalline form of the compound of formula (I) is a free-form crystalline form C having DSC/TGA graphs that are substantially those shown in FIG. 10.

10 As a further preferred embodiment, the crystalline form of the compound of formula (I) in free form is a crystalline form D having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of 7.97±0.2°, 11.82±0.2°, 12.18±0.2°, 14.87±0.2°, 16.13±0.2°, 17.18±0.2°, 19.21±0.2°, 20.72±0.2° and 25.28±0.2°.

15 As a more further preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form D comprises peaks substantially identical (±0.2°) to those at angles of diffraction (2θ) shown in FIG. 4, and X-ray powder diffraction data thereof are shown in Table 4:

Table 4

2θ (°)	Intensity%	2θ (°)	Intensity%
6.06	12.4%	18.81	14.5%
7.97	100.0%	19.21	19.4%
11.82	66.7%	20.72	58.4%
12.18	50.6%	21.55	11.7%
14.87	22.9%	24.48	13.2%
15.48	13.6%	25.28	37.9%
16.13	61.3%	27.88	10.9%
17.18	60.5%		

The crystalline form is designated free-form crystalline form D and has a melting point of 239.9 °C.

As the most preferred embodiment, the crystalline form of the compound of formula (I) is a free-form crystalline form D having DSC/TGA graphs that are substantially those shown in FIG. 11.

As a further preferred embodiment, the crystalline form of the compound of formula (I) in free form is a crystalline form E having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of 8.16±0.2°, 12.05±0.2°, 12.83±0.2°, 15.19±0.2°, 16.18±0.2°, 16.59±0.2°, 17.62±0.2°, 18.41±0.2°, 22.90±0.2° and 25.65±0.2°.

As a more further preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form E comprises peaks substantially identical (±0.2°) to those at angles of diffraction (2θ) shown in FIG. 5, and X-ray powder diffraction data thereof are shown in Table 5:

Table 5

2θ (°)	Intensity%	2θ (°)	Intensity%
6.37	9.4%	17.62	100.0%
8.16	46.1%	18.41	25.3%
12.05	74.6%	19.59	18.8%
12.83	36.5%	20.57	6.6%
14.50	11.2%	21.33	7.7%
15.19	24.7%	22.90	50.8%
16.18	32.6%	25.65	24.7%
16.59	47.8%		

The crystalline form is designated free-form crystalline form E and has a melting point of 226 °C.

As the most preferred embodiment, the crystalline form of the compound of formula (I) is a free-form crystalline form E having a DSC graph that is substantially the one shown in FIG. 12.

As a further preferred embodiment, the crystalline form of the compound of formula (I) in free form is a crystalline form F having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of 6.92±0.2°, 9.10±0.2°, 12.42±0.2°, 13.46±0.2°, 14.38±0.2°, 15.84±0.2°, 19.04±0.2°, 22.00±0.2° and 26.23±0.2°.

As a more further preferred embodiment, the X-ray powder diffraction (XRPD) pattern of the crystalline form F comprises peaks substantially identical (±0.2°) to those at angles of diffraction (2θ) shown in FIG. 6, and X-ray powder diffraction data thereof are shown in Table 6:

Table 6

2θ (°)	Intensity%	2θ (°)	Intensity%
5.79	10.7%	14.38	42.9%
6.92	40.6%	15.84	59.3%
9.10	100.0%	19.04	11.8%

11.39	8.1%	22.00	12.0%
12.42	24.0%	26.23	13.7%
13.46	21.1%		

The crystalline form is designated free-form crystalline form F and has a melting point of 221 °C.

As the most preferred embodiment, the crystalline form of the compound of formula (I) is a free-form crystalline form F having DSC/TGA graphs that are substantially those shown in FIG. 13.

A fifth aspect of the present invention provides a use of the aforementioned crystalline form of the compound of formula (I) in free form, wherein the crystalline form of the compound of formula (I) in free form is used as a starting material to prepare the crystalline basic salt of the compound of formula (I) according to any one of the above.

A sixth aspect of the present invention provides a pharmaceutical composition comprising a clinically effective amount of the aforementioned crystalline basic salt of the compound of formula (I) or the crystalline form of the compound of formula (I) in free form and a pharmaceutically acceptable carrier.

As a preferred embodiment, the clinically effective amount means that the pharmaceutical composition comprises 0.01-99.0% W/W of the crystalline basic salt of the compound of formula (I) or the crystalline form of the compound of formula (I) in free form relative to a total content of the pharmaceutical composition.

A seventh aspect of the present invention provides a use of the aforementioned crystalline basic salt of the compound of formula (I) or the aforementioned crystalline form of the compound of formula (I) in free form in preparation of a medicament for treating a PD-1/PD-L1 signal pathway-mediated tumor, immunity-related disease and disorder, communicable disease, infectious disease or metabolic disease; preferably, the tumor is cancer.

As a preferred embodiment, the infectious disease is a bacterial infectious disease, a viral infectious disease or a fungal infectious disease.

As a preferred embodiment, the tumor is lymphoma, sarcoma, melanoma, glioblastoma, synovioma, meningioma, biliary tract tumor, neuroma, seminoma, nephroblastoma, hepatocellular papilloma, papilloma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, lipoma, fibroma, central nervous system tumor, spinal axis tumor, brain stem glioma, multiple myeloma, ovarian tumor, myelodysplastic syndrome or mesothelioma, anal cancer, testicular cancer, urethral carcinoma, penile cancer, bladder cancer, ureteral cancer, uterine cancer, ovarian cancer, fallopian tube cancer, cervical cancer, vaginal cancer, vulvar cancer, Merkel cell carcinoma, embryonal carcinoma, chronic or acute leukemia, bronchial carcinoma, esophageal cancer,

nasopharyngeal carcinoma, hepatocellular carcinoma, basal cell carcinoma, lung cancer, adenocarcinoma, papillary carcinoma, rectal cancer, colon cancer, gastric cancer, head and neck cancer, bone cancer, skin cancer, small intestine cancer, endocrine cancer, renal pelvic carcinoma, epidermoid carcinoma, transitional cell carcinoma or choriocarcinoma;

5 the immunity-related disease and disorder is rheumatic arthritis, renal failure, lupus erythematosus, asthma, psoriasis, ulcerative colitis, pancreatitis, allergy, fibrosis, anemia, fibromyalgia, Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, Crohn's disease, ulcerative colitis, allergic contact dermatitis and eczema, systemic sclerosis or multiple sclerosis;

10 the communicable disease or infectious disease is sepsis, liver infection, hepatitis A, hepatitis B, hepatitis C, hepatitis D, herpes virus, papillomavirus or influenza; and

 the metabolic disease is diabetes, diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, hypoglycemia, gout, malnutrition, vitamin A deficiency, scurvy, vitamin D deficiency or osteoporosis.

15 As a preferred embodiment, the lymphoma is lymphocytic lymphoma, primary central nervous system lymphoma, T cell lymphoma, diffuse large B cell lymphoma, follicle center lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma or primary mediastinal large B cell lymphoma;

 the sarcoma is Kaposi's sarcoma, fibrosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, leiomyosarcoma, rhabdomyosarcoma, soft tissue sarcoma, angiosarcoma or lymphangiosarcoma; and

20 the chronic or acute leukemia is acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic granulocytic leukemia or chronic lymphoblastic leukemia.

25 As a preferred embodiment, the tumor is small cell lung cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, chondroma, colorectal cancer, gastrointestinal cancer, endometrial cancer, head and neck squamous cell carcinoma, abdominal wall carcinoma, renal cell carcinoma or recurrent or existing drug-resistant prostate cancer.

30 As a preferred embodiment, the tumor is thymic tumor, pleomorphic adenoma, renal tubule adenoma, cystadenoma, pituitary adenoma, prostate cancer, thyroid cancer, parathyroid cancer, adrenal cancer, breast cancer, cystadenocarcinoma or pancreatic cancer.

35 An eighth aspect of the present invention provides the aforementioned crystalline basic salt of the compound of formula (I) or the aforementioned crystalline form of the compound of formula (I) in free form for use as a medicament for treating a PD-1/PD-L1 signal pathway-mediated tumor, immunity-related disease and disorder, communicable disease, infectious disease or metabolic disease.

40

The present invention also relates to a method for treating a PD-1/PD-L1 signal pathway-mediated tumor, immunity-related disease and disorder, communicable disease, infectious disease or metabolic disease, comprising administering to a patient in need thereof the aforementioned crystalline basic salt of the compound of formula (I) or the
5 aforementioned crystalline form of the compound of formula (I) in free form.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows an X-ray powder diffraction pattern of the crystalline form A of disodium salt hydrate of the compound of formula (I) of the present invention. The
10 abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

FIG. 2 shows an X-ray powder diffraction pattern of the crystalline form B of disodium salt anhydrate of the compound of formula (I) of the present invention. The abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

FIG. 3 shows an X-ray powder diffraction pattern of the free-form crystalline form
15 C of the compound of formula (I) of the present invention. The abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

FIG. 4 shows an X-ray powder diffraction pattern of the free-form crystalline form D of the compound of formula (I) of the present invention. The abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

FIG. 5 shows an X-ray powder diffraction pattern of the free-form crystalline form
20 E of the compound of formula (I) of the present invention. The abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

FIG. 6 shows an X-ray powder diffraction pattern of the free-form crystalline form
25 F of the compound of formula (I) of the present invention. The abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

FIG. 7 shows the structure of a unit cell of a single crystal of the crystalline form A of disodium salt hydrate of the compound of formula (I) of the present invention.

FIG. 8 shows DSC/TGA graphs of the crystalline form A of disodium salt hydrate of the compound of formula (I) of the present invention. The abscissa represents
30 temperature ($^{\circ}\text{C}$), the left ordinate represents heat flow (w/g), and the right ordinate represents weight (%).

FIG. 9 shows DSC/TGA graphs of the crystalline form B of disodium salt anhydrate of the compound of formula (I) of the present invention. The abscissa represents
35 temperature ($^{\circ}\text{C}$), the left ordinate represents heat flow (w/g), and the right ordinate represents weight (%).

FIG. 10 shows DSC/TGA graphs of the free-form crystalline form C of the compound of formula (I) of the present invention. The abscissa represents temperature ($^{\circ}\text{C}$), the left ordinate represents weight (%), and the right ordinate represents heat flow (w/g).

40 FIG. 11 shows DSC/TGA graphs of the free-form crystalline form D of the

compound of formula (I) of the present invention. The abscissa represents temperature (°C), the left ordinate represents heat flow (w/g), and the right ordinate represents weight (%).

FIG. 12 shows a DSC graph of the free-form crystalline form E of the compound of formula (I) of the present invention. The abscissa represents temperature (°C), and the ordinate represents heat flow (w/g).

FIG. 13 shows DSC/TGA graphs of the free-form crystalline form F of the compound of formula (I) of the present invention. The abscissa represents temperature (°C), the left ordinate represents heat flow (w/g), and the right ordinate represents weight (%).

FIG. 14 shows a DVS graph of the free-form crystalline form C of the compound of formula (I) of the present invention. The abscissa represents relative humidity (%), and the ordinate represents weight change (%).

FIG. 15 shows a DVS graph of the free-form crystalline form D of the compound of formula (I) of the present invention. The abscissa represents relative humidity (%), and the ordinate represents weight change (%).

FIG. 16 shows a DVS graph of the free-form crystalline form F of the compound of formula (I) of the present invention. The abscissa represents relative humidity (%), and the ordinate represents weight change (%).

FIG. 17 shows a DVS graph of the crystalline form A of disodium salt hydrate of the compound of formula (I) of the present invention. The abscissa represents relative humidity (%), and the ordinate represents weight change (%).

FIG. 18 shows an X-ray powder diffraction pattern of an amorphous potassium salt of the compound of formula (I) of the present invention. The abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

FIG. 19 shows an X-ray powder diffraction pattern of an amorphous arginine salt of the compound of formula (I) of the present invention. The abscissa represents the value of 2θ (degrees), and the ordinate represents peak intensity.

DETAILED DESCRIPTION OF THE INVENTION

The inventors of the present invention have intensively studied different aggregate forms of the compound of formula (I) and provide a crystalline free form of the PD-1/PD-L1 inhibitor or a basic salt thereof. The crystalline free form of the compound greatly improves physicochemical properties, such as hygroscopicity, solubility and physicochemical stability, of the compound of formula (I), and the crystalline basic salt of the compound greatly improves physicochemical properties such as solubility and physicochemical stability, so that the crystalline free form of the compound of formula (I) or the basic salt thereof can satisfy the need to develop clinical pharmaceutical formulations, has very important clinical application value, can be widely applied to the preparation of drugs for treating tumors, immunity-related diseases and disorders,

communicable diseases, infectious diseases or metabolic diseases, particularly drugs for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic diseases, neurodegenerative diseases, primary tumor metastasis or metastatic cancer in bones, and is expected to be developed into a new-generation PD-1/PD-L1 inhibitor drug soon. The present invention is achieved on this basis.

Detailed description: Unless otherwise stated, the following terms used in the specification and claims have the following meanings.

“Pharmaceutical composition” refers to a mixture containing one or more of the compounds described herein or a physiologically/pharmaceutically acceptable salt or pro-drug thereof and other chemical components, as well as other components such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to promote administration to an organism and facilitate the absorption of the active ingredient, so that the active ingredient can exert biological activity.

The compound of formula (I) has a variety of separated free forms or basic salts, showing polymorphism or monomorphism. For example, each of the sodium salts is shown as a polymorph. These “polymorphs” differ in terms of their X-ray powder diffraction patterns, physicochemical and pharmacokinetic properties and thermodynamic stability.

As used herein, “salt” refers to a compound prepared by reacting an organic acid or base medicament with a pharmaceutically acceptable inorganic or organic acid or base.

Methods and Materials

Diffraction data of the crystalline free form of the compound of formula (I) or the basic salt thereof were collected at room temperature using a Bruker D8 ADVANCE (Bruker, Germany) X-ray powder diffractometer with an X-ray source of Cu K α ($\lambda = 1.5406 \text{ \AA}$, light tube voltage, current: 40 kV, 40 mA). When a sample was prepared, an appropriate amount of the sample was placed on a zero-background sample tray, and the surface was flattened by gently pressing. The scan range for the sample was from 3° to 40° (2θ), the step size was 0.02° (2θ), and the duration of each step of scanning was 0.02 s. Diffraction patterns were analyzed using DIFFRAC.EVA (V4.3.1). Measurement differences associated with such X-ray powder diffraction analyses result from a variety of factors including: (a) errors in sample preparation (e.g., sample height), (b) instrument errors, (c) calibration errors, (d) operator errors (including those errors present when determining peak positions), and (e) the nature of the material (e.g., preferred orientation errors). Calibration errors and sample height errors often result in a shift of all the peaks in the same direction. In general, this calibration factor will cause the measured peak positions to be in agreement with the expected peak positions and may be in the range of the expected 2θ value $\pm 0.2^\circ$. The angle 2θ values ($^\circ$) and intensity values (as a % of the

value of the highest peak) for each polymorph obtained in the examples of the present invention are shown in Tables 1-6.

The experimental method of characterizing the crystalline free form of the compound of formula (I) or the basic salt thereof using differential scanning calorimetry (DSC) is as follows: a small amount of the crystalline sample was placed in an aluminum pan that was compatible with the instrument and could be covered with a lid; after the sample was loaded, the aluminum pan was covered with a lid and then placed into the instrument for analysis. In this patent, all the instruments used for differential scanning calorimetry were TA Discovery DSC25, the scanning parameter was set to using a nitrogen atmosphere, and the warming rate was 10 °C/min.

The experimental method of characterizing the crystalline free form of the compound of formula (I) or the basic salt thereof using thermogravimetric analysis (TGA) is as follows: a small amount of the crystalline sample was placed in an aluminum pan that was compatible with the instrument; after the sample was loaded, the aluminum pan was placed into the instrument for analysis. In this patent, all the instruments used for thermogravimetric analysis were TA Discovery TGA550, the scanning parameter was set to using a nitrogen atmosphere, and the warming rate was 10 °C/min.

The experimental method of characterizing the crystalline free form of the compound of formula (I) or the basic salt thereof using dynamic vapor sorption (DVS) is as follows: a small amount of the crystalline sample was placed in a precision sample tray that was compatible with the instrument; after the sample was loaded, the sample tray was placed into the instrument for analysis. In this patent, the instruments used for dynamic vapor sorption were all the DVS Intrinsic plus model, and the following experimental parameters were set: nitrogen was used as the carrier gas, a constant temperature of 25 °C was set, the rate of mass percentage change over a unit of time (dm/dt) = 0.002%/min was used as a criterion for determining if equilibrium is reached, and the program humidity change cycle was set to 50-95-0-95-50% RH; within the range of 0-90% RH, a change of 10% RH was taken as a step, and within the range of 90% RH-95% RH, a change of 5% RH was taken as a step.

The stability and solubility of the crystalline free form of the compound of formula (I) or the basic salt thereof of the present application were determined by HPLC. The specific test method is shown in the table below.

Instrument	Thermo HPLC
Chromatographic column	Xbridge-C18
Chromatographic column supplier	Waters
Particle size (μm)	3.5
Size (mm)	4.6 × 150
Column temperature (°C)	40
Flow rate (mL/minute)	0.8
Injection volume (μL)	10

Dilution solvent	MeOH	
Sample concentration (µg/mL)	400	
Wavelength (nm)	277	
Mobile phase A	0.1% TFA in water	
Mobile phase B	0.1% TFA in acetonitrile	
Run time (minutes)	21.0	
Elution gradient	% B	Minutes
	5	Initial
	95	19
	95	20
	5	20.1
	5	21

The reagents in the examples of the present invention are known and commercially available, or can be synthesized using or according to methods known in the art. The starting material used in the study was prepared according to Patent No. WO2019149183A1, or was optionally subjected to conventional treatment in the art to obtain a free form.

Unless otherwise stated, all reactions of the present invention are carried out in a dry nitrogen or argon atmosphere with continuous magnetic stirring, the solvent is a dry solvent, and the temperature is in degrees centigrade (°C).

Unless otherwise specified, each of the various crystalline forms referred to in the present invention may be an anhydrous crystalline form or a hydrated crystalline form. For example, it is a hydrated crystalline form; preferably, each molecule of the crystal contains 1, 2, 3, 4 or 5 waters of crystallization; and more preferably, each molecule of the crystal contains 2 or 4 waters of crystallization.

The present invention is further explained in detail below using the drawings and specific examples, which are illustrative only of particular embodiments of the present invention and should not be construed as limiting the scope of the present invention in any way.

Preparation of Specific Examples

Example 1. Preparation of Crystalline Form A of Disodium Salt Hydrate

About 10 mg of the compound of formula (I) in free form was dissolved in 0.5 mL of ethanol/water (volume ratio: 10:1), and a solution of 2 equivalents of sodium hydroxide in ethanol/water was added. The mixture was stirred at room temperature for 3 days and filtered, and the filter cake was dried in a drying oven at 50 °C. The crystalline form A of disodium salt hydrate was a solid with high crystallinity and had a solid-solid crystalline form transformation peak at 237.3 °C.

Analysis showed that the crystalline form had the XRPD pattern shown in FIG. 1 and the DSC/TGA graphs shown in FIG. 8.

Example 2. Preparation of Crystalline Form B of Disodium Salt Anhydrate

About 10 mg of the crystalline form A of disodium salt hydrate of the compound of formula (I) was heated to 245 °C to obtain the crystalline form B of disodium salt anhydrate, which had a melting point of 316.4 °C. The crystalline form B of disodium salt anhydrate was a solid with high crystallinity.

5 Analysis showed that the crystalline form had the XRPD pattern shown in FIG. 2 and the DSC/TGA graphs shown in FIG. 9.

Example 3. Preparation of Free-Form Crystalline Form C

10 About 25 mg of the compound of formula (I) in free form was added to 200 µL of ethyl acetate and suspended at 45 °C for 7 days. A solid sample was then isolated by centrifugation and dried under vacuum at 40 °C overnight. The free-form crystalline form C was a solid with high crystallinity and had a melting peak at 169.5 °C.

Analysis showed that the crystalline form had the XRPD pattern shown in FIG. 3 and the DSC/TGA graphs shown in FIG. 10.

Example 4. Preparation of Free-Form Crystalline Form D

15 About 10 mg of the compound of formula (I) in free form was added to 200 µL of ethyl acetate and suspended at 45 °C for 7 days. The mixture was filtered, and the filter cake was dried in a drying oven at 50 °C. The free-form crystalline form D was a solid with moderate crystallinity, and DSC showed a melting peak at 239.9 °C.

20 Analysis showed that the crystalline form had the XRPD pattern shown in FIG. 4 and the DSC and TGA graphs shown in FIG. 11.

Example 5. Preparation of Free-Form Crystalline Form E

25 5 mg of the free-form crystalline form C of the compound of formula (I) was heated to 166 °C to obtain a solid sample of the free-form crystalline form E. The free-form crystalline form E was a solid with moderate crystallinity and had a melting peak at 224.7 °C.

Analysis showed that the crystalline form had the XRPD pattern shown in FIG. 5 and the DSC graph shown in FIG. 12.

Example 6. Preparation of Free-Form Crystalline Form F

30 5 mg of the compound of formula (I) in free form was added to 200 µL of methanol and suspended at 50 °C for 7 days. Then, a solid sample was separated by centrifugation and dried under vacuum at 40 °C overnight. The free-form crystalline form F was a solid with moderate crystallinity and had a melting peak at 221.1 °C.

Analysis showed that the crystalline form had the XRPD pattern shown in FIG. 6 and the DSC and TGA graphs shown in FIG. 13.

Example 7. Preparation of Amorphous Potassium Salt

35 About 10 mg of the compound of formula (I) in free form was dissolved in 0.5 mL of trifluoroethanol, and a solution of 2 equivalents of potassium hydroxide in trifluoroethanol was added. The mixture was stirred at room temperature for 3 days and filtered, and the filter cake was dried in a drying oven at 50 °C.

40 Analysis showed that the product had the XRPD pattern shown in FIG. 18. The

potassium salt obtained was an amorphous solid.

Example 8. Preparation of Amorphous Arginine Salt

About 10 mg of the compound of formula (I) in free form was dissolved in 0.5 mL of trifluoroethanol, and a solution of 2 equivalents of arginine in trifluoroethanol was added. The mixture was stirred at room temperature for 3 days and filtered, and the filter cake was dried in a drying oven at 50 °C.

Analysis showed that the product had the XRPD pattern shown in FIG. 19. The arginine salt obtained was an amorphous solid.

Example 9. Single Crystal Structure Analysis of Crystalline Form A of Disodium Salt Hydrate

1. Experimental instruments

Transmission electron microscope: Thermo Scientific Glacios

Detector: Thermo Scientific Ceta-D

Sample rod: Autoloader

2. Experimental conditions

Voltage: 200 kV

Temperature: 83 K

Vacuum value: 10^{-7} Pa high vacuum

3. Application software

Data collection: Thermo Scientific EPU-D

Data processing: XDS, SHELXT and SHELXL

4. Sample preparation

A small amount of the powdered sample was directly transferred onto a TEM grid, and the excess powder was blown away with a rubber bulb. The grid was rapidly plunged into liquid ethane using a Thermo Scientific Vitrobot cryo-electron microscope sample preparation system. After being frozen, the sample was transferred to liquid nitrogen for storage and then loaded into the electron microscope for observation.

5. Image collection

Multiple particles of appropriate size with clear diffraction signals were selected, and a series of diffraction data generated by rotation of the particles were collected automatically using EPU-D software.

6. Data processing

The diffraction images were indexed and subjected to intensity integration to obtain unit cell parameters and HKL files. Multiple sets of data were merged to solve the crystal structure.

7. Analysis results

From 26 different particles of the sodium salt of the compound of formula (I), 19 sets of diffraction images were collected. These images were each indexed and integrated using XDS, and the following unit cell constants were obtained: $a = 20.00(5) \text{ \AA}$, $b = 5.798(16) \text{ \AA}$, $c = 20.44(11) \text{ \AA}$, $\alpha = 90^\circ$, $\beta = 94.8(2)^\circ$, $\gamma = 90^\circ$ and unit cell volume $V =$

2362(15) Å³.

8. Structure determination

The 9 best-quality sets of data were merged using XSCALE. The total data set contained a total of 16,135 diffraction points, of which 2821 were independent diffraction points. From the above data, the crystal structure of the crystalline form A of disodium salt hydrate was successfully determined. It is a monoclinic crystal system with a space group of C2 (No. 5), a molecular weight of 450.48 g·mol⁻¹ and Z' = 0.5. The asymmetric unit consists of 0.5 API anions, 1 sodium ion and 2 water molecules. The structure of a unit cell of the single crystal is shown in FIG. 7. Crystallographic data and refinement parameters are shown in the table below.

Chemical formula	C ₄₆ H ₅₀ N ₆ O ₆ ⁻ · 2Na ⁺ · 4H ₂ O
Molecular weight	900.97 g·mol ⁻¹
Temperature	83(2) K
Wavelength	0.02508 Å
Crystal system, space group	Monoclinic, C2 (No. 5)
Unit cell parameters	a = 20.00(5) Å b = 5.798(16) Å c = 20.44(11) Å α = 90° β = 94.8(2)° γ = 90°
Volume	2362(15) Å ³
Z'	0.5
Density	1.267 g/cm ³
Resolution	0.90 Å
All diffraction points	16135
Independent diffraction points	2821
Completeness	82.7 %
R_{int}	0.2522
Initial model generation method	<i>ab initio</i>
Hydrogen atom refinement	Geometric constraints
Goodness-of-fit on F²	1.284
R₁ [I ≥ 2σ(I)]	0.1534
R₁ [all data]	0.1736
wR₂[I ≥ 2σ(I)]	0.3589
wR₂[all data]	0.3752

Example 10. Solubility Determination

The desired amount of the compound was weighed into a glass vial, and the desired amount of a vehicle was added. A stir bar was added to the vial, and the mixture was stirred at room temperature for 24 hrs. After 24 hrs, the appearance of the sample was observed. An appropriate amount of the sample was filtered through a PVDF 0.45 μm filter membrane, and the filtrate was collected. The pH value of the filtrate was determined, and the sample was diluted with MeOH. The diluted sample was injected

into an HPLC system to determine the concentration.

The process of preparing pH buffers is shown in the table below:

pH value	Preparation process
1.2	8.5 mL of a 0.2 M hydrochloric acid solution and 5 mL of a 0.2 M potassium chloride solution were added to a 20 mL volumetric flask, and the mixture was brought to volume with water and well mixed. The pH value was determined, and the pH should be 1.2 ± 0.03 . The pH was adjusted to 1.2 with hydrochloric acid or sodium hydroxide if necessary.
4.7	359 mg of sodium acetate trihydrate solid was weighed into a 100 mL volumetric flask, and an appropriate amount of water was added to dissolve the solid. Then, 1.18 mL of a 2 N acetic acid solution was transferred into the volumetric flask, and the mixture was brought to volume with water and well mixed. The pH value was determined, and the pH should be 4.7 ± 0.03 .
6.8	169.96 mg of anhydrous potassium dihydrogen phosphate and 29.17 mg of sodium hydroxide were added to a 25 mL volumetric flask, and the solution was brought to volume with purified water. The pH was adjusted to 6.8 with phosphoric acid.

The process of preparing biological media is shown in the table below:

Biological medium	Preparation process
FaSSIF fasted-state simulated intestinal fluid	1.0471 g of concentrated FaSSIF solution was weighed into a 25 mL volumetric flask and diluted with an appropriate amount of purified water, and 55.9 mg of FaSSIF/FeSSIF/FaSSGF powder was added. The mixture was brought to volume (25 mL) and well mixed (pH 6.5).
FeSSIF fed-state simulated intestinal fluid	2.0365 g of concentrated FeSSIF solution was weighed into a 25 mL volumetric flask and diluted with an appropriate amount of purified water, and 280.2 mg of FaSSIF/FeSSIF/FaSSGF powder was added. The mixture was brought to volume (25 mL) and well mixed (pH 5.0).
FaSSGF simulated gastric fluid	3.6790 g of concentrated FaSSGF solution was weighed into a 100 mL volumetric flask and diluted with an appropriate amount of purified water, and 6.0 mg of FaSSIF/FeSSIF/FaSSGF powder was added. The mixture was brought to volume (100 mL) and well mixed (pH 1.6).
Note	The concentrated FaSSIF solution, concentrated FeSSIF solution and concentrated FaSSGF solution and FaSSIF/FeSSIF/FaSSGF powders used are all commercially available products (supplier: Biorelevant).

The experimental results are shown below:

No.	Vehicle	Target concentration (µg/mL)	Equilibrium solubility (µg/mL, pH ₂₄ hrs)		
			Solubility of crystalline form C (µg/mL, pH ₂₄ hrs)	Solubility of crystalline form D (µg/mL, pH ₂₄ hrs)	Solubility of crystalline form F (µg/mL, pH ₂₄ hrs)
1	Water	2000	3.84(6.78)	51.93(5.82)	69.47(5.52)
2	pH 1.2, HCl 100 mM		18.92(1.30)	281.84(1.16)	244.49(1.15)
3	pH 4.7, 50 mM acetic acid buffer		3.3(4.77)	47.41(4.73)	67.33(4.68)
4	pH 6.8, 50 mM phosphoric acid buffer		2.31(6.89)	42.11(6.90)	61.01(6.93)
5	FaSSGF		8.9(1.56)	87.01(1.57)	117.15(1.58)
6	FaSSIF		3.21(6.41)	78.44(6.43)	306.56(6.42)
7	FeSSIF		5.34(4.90)	433.75(4.94)	1723.16(4.99)

As can be seen from the above data, the free-form crystalline form C exhibited improved solubility in the buffer system having a pH of 1.2 compared to the other test conditions. Compared to the free-form crystalline form C, the free-form crystalline form D and free-form crystalline form F had solubility values that were increased by a factor of at least 10 or more under various test conditions, such as buffer systems having a pH of 1.2-6.8, water and simulated biological media (FaSSGF, FaSSIF and FeSSIF), indicating significantly improved solubility. More surprisingly, compared to the free-form crystalline form C, the free-form crystalline form F had a solubility value that was increased by a factor of nearly one hundred in the simulated biological medium FaSSIF and a solubility value that was increased by a factor of several hundreds in the simulated biological medium FeSSIF.

Solubility data of crystalline form A of disodium salt hydrate and crystalline form B of disodium salt anhydrate

No.	Solvent/medium	Target concentration (µg/mL)	Equilibrium solubility (µg/mL, pH ₂₄ hrs)	
			Solubility of crystalline form B (µg/mL, pH ₂₄ hrs)	Solubility of crystalline form A (µg/mL, pH ₂₄ hrs)
1	Water	2000	≥2000(9.96)	>2000(9.61)
2	pH 1.2, HCl 100 mM		≥2000(0.95)	1120(1.01)

3	pH 4.7, 50 mM acetic acid buffer		135(4.92)	25(4.61)
4	pH 6.8, 50 mM phosphoric acid buffer		194(7.03)	34(6.88)
5	FaSSGF		485(1.72)	22(1.73)
6	FaSSIF		474(6.93)	303(6.93)
7	FeSSIF		≥2000(6.90)	>2000(7.95)

As can be seen from the above data, the crystalline sodium salts of the compound of formula (I) exhibited significantly improved solubility, which was at least several tens of times higher than that of the free-form crystalline form C of the compound of formula (I). In particular, the crystalline form B of disodium salt anhydrate exhibited excellent solubility in various buffers and biological medium solutions.

Example 11. Stability Determination

An appropriate amount of the sample was placed in a vial and left to stand at 50 °C, 80 °C or 50 °C & 75% RH (open) for 7 days to evaluate thermal stability. An appropriate amount of the sample was placed in a transparent vial, an amber vial or an aluminum foil transparent vial and left to stand in a light box for 10 days to obtain a photostability evaluation under conditions of overall near-ultraviolet energy of 1.2×10^6 Lux·hr and no less than 200 W·hr/m². The experimental results are shown below.

Stability data of free-form crystalline form C

Condition	Time	Appearance	Purity (%)	XRPD
Initial	0 days	White powder	98.42	Free-form crystalline form C
50 °C/75%RH	7 days	White powder	98.43	Free-form crystalline form C
50 °C	7 days	White powder	98.31	Free-form crystalline form C
80 °C	7 days	White powder	97.90	Free-form crystalline form C
Transparent light exposure	9.2 days	White powder	97.91	Free-form crystalline form C
Aluminum foil light exposure control	9.2 days	White powder	98.51	Free-form crystalline form C

Stability data of free-form crystalline form D

Condition	Time	Appearance	Purity (%)	XRPD
Initial	0 days	White	98.17	Free-form crystalline

		powder		form D
50 °C/75%RH	7 days	White powder	98.24	Free-form crystalline form D
50 °C	7 days	White powder	98.13	Free-form crystalline form D
80 °C	7 days	White powder	97.22	Free-form crystalline form D
Transparent light exposure	9.2 days	White powder	96.06	Free-form crystalline form D
Aluminum foil light exposure control	9.2 days	White powder	98.26	Free-form crystalline form D

Stability data of free-form crystalline form F

Condition	Time	Appearance	Purity (%)	XRPD
Initial	0 days	White powder	99.44	Free-form crystalline form F
50 °C/75%RH	11 days	White powder	99.36	Free-form crystalline form F
50 °C	11 days	White powder	99.36	Free-form crystalline form F
80 °C	11 days	White powder	99.22	Free-form crystalline form F
Transparent light exposure	9.2 days	White powder	99.43	Free-form crystalline form F
Aluminum foil light exposure control	9.2 days	White powder	99.39	Free-form crystalline form F

Stability data of crystalline form A of disodium salt hydrate

Condition	Time	Appearance	Purity (%)	XRPD
Initial	0 days	White powder	99.38	Crystalline form A of disodium salt
50 °C	7 days	White powder	99.45	Crystalline form A of disodium salt
80 °C	7 days	White powder	99.34	Crystalline forms A + B of disodium salt
50 °C/75%RH	7 days	White powder	99.46	Crystalline form A of disodium salt
Transparent light exposure	9.2 days	White powder	99.22	Crystalline forms A + B of disodium salt
Brown vial light exposure control	9.2 days	White powder	99.50	Crystalline form A of disodium salt
Aluminum foil light exposure	9.2 days	White powder	99.51	Crystalline form A of disodium salt

control				
---------	--	--	--	--

Stability data of crystalline form B of disodium salt anhydrate

Condition	Time	Appearance	Purity (%)	XRPD
Initial	0 days	White powder	91.23	Crystalline form B of disodium salt
50 °C	7 days	White powder	92.11	Crystalline form B of disodium salt
80 °C	7 days	White powder	90.77	Crystalline form B of disodium salt
50 °C/75%RH	7 days	White powder	92.97	Crystalline form B of disodium salt
Transparent light exposure	9.2 days	White powder	83.10	Crystalline form B of disodium salt
Brown vial light exposure control	9.2 days	White powder	88.10	Crystalline form B of disodium salt
Aluminum foil light exposure control	9.2 days	White powder	89.50	Crystalline form B of disodium salt

As can be seen from the above results,

- Under conditions of 50 °C, 50 °C/75% RH (open), 80 °C for 7 days and photostress for 10 days and overall near-ultraviolet energy of 1.2×10^6 Lux·hr and no less than 200 W·hr, the free-form crystalline form C, crystalline form D and crystalline form F all exhibited extremely high physical and chemical stability.
- The crystalline form A of disodium salt hydrate exhibited good chemical stability under various stability testing conditions, with no significant increase in impurity content; however, the crystalline form underwent crystalline form transformation under high temperature and light exposure. The crystalline form B of disodium salt anhydrate exhibited good physical stability under the stability testing conditions, and no crystalline form transformation was observed; however, the crystalline form was sensitive to light exposure. Therefore, the development of the crystalline forms of disodium salt requires attention to storage conditions, and high temperatures and exposure to light should be avoided.

Example 12. Hygroscopic Behavior Test

In the present invention, the hygroscopic weight increases (hygroscopic weight increase/weight before hygroscopy * 100%) of various crystalline forms under various relative humidity conditions were determined using the dynamic vapor sorption method, and the hygroscopicity of different crystalline compounds was evaluated. The results are shown in FIGs. 14-17 and the table below:

Hygroscopic weight increase (%)	Relative humidity (%) at 25 °C										
	0.0	10.0	20.0	30.0	40.0	50.0	60.0	65.0	70.0	80.0	90.0

Crystalline form											
Free-form crystalline form C	0.00	0.50	0.75	0.80	1.20	1.35	1.50	/	1.75	2.21	2.95
Free-form crystalline form D	0.00	0.40	0.85	1.34	1.85	2.30	2.76	/	3.25	3.79	4.58
Free-form crystalline form F	0.00	0.18	0.38	0.60	0.84	1.14	1.54	/	2.04	2.55	3.28
Crystalline form A of disodium salt hydrate	0.00	2.40	7.45	9.28	10.62	11.64	12.43		13.25	14.59	/
Amorphous potassium salt	/	/	/	/	/	/	/	5.12	/	12.98	26.64

Note: “/” means “no detection”.

As can be seen from the above data, the free-form crystalline form C, crystalline form D and crystalline form F were all moderately hygroscopic, and showed no crystalline form changes after DVS testing.

- 5 The crystalline form A of disodium salt hydrate and the amorphous potassium salt exhibited comparable hygroscopicity, their weight increased by more than 10% at 80% RH, and they showed no crystalline form changes after DVS testing.

- 10 As can be seen from the above experimental results, the free-form crystalline form C has high crystallinity, allows for scale-up preparation, has moderate hygroscopicity, and exhibits extremely high physical and chemical stability under various stability testing conditions. However, the free-form crystalline form C exhibits improved solubility only in a buffer system having a pH of 1.2.

- 15 The free-form crystalline form D has moderate crystallinity, allows for scale-up preparation, has moderate hygroscopicity, and exhibits extremely high physical and chemical stability under various stability testing conditions. In addition, the free-form crystalline form D exhibits significantly improved solubility under various pH conditions.

The free-form crystalline form E has moderate crystallinity, and its scale-up preparation is not easy at present.

- 20 The free-form crystalline form F has moderate crystallinity, allows for scale-up preparation, has moderate hygroscopicity, and exhibits extremely high physical and chemical stability under various stability testing conditions. In addition, the free-form crystalline form F exhibits extremely significantly improved solubility under various pH conditions.

- 25 After salt-forming screening of a large number of basic salts, only crystalline salt forms of the sodium salt, specifically the crystalline form A of disodium salt hydrate and the crystalline form B of anhydrate, were obtained. The sodium salt can be used to prepare salt forms with high crystallinity and allows for scale-up preparation. In addition, under different pH conditions or in various biological media, various crystalline forms of the sodium salt all exhibit significantly higher solubility than the free-form crystalline form C.
- 30 C.


Specifically, the crystalline form A of disodium salt hydrate exhibits relatively high physical and chemical stability under various conditions, such as 50 °C, 50 °C/75% RH or brown light exposure, and under high temperature and light exposure, it exhibits relatively high chemical stability but undergoes crystalline form transformation. In
5 further development of formulations or storage and transportation, it is necessary to avoid exposure to light, and the ambient temperature should not be kept too high.

The crystalline form B of disodium salt anhydrate exhibits relatively high physical and chemical stability under various conditions, such as 50 °C, 50 °C/75% RH or brown light exposure; and it exhibits relatively high physical stability under high temperature
10 and high humidity conditions but is sensitive to light. In further development of formulations or storage and transportation, it is necessary to avoid exposure to light.

All documents mentioned in the present invention are incorporated as references, just as each document is individually cited as a reference. In addition, it should be understood that various modifications or changes may be made by those skilled in the art
15 after reading the above teachings of the present invention, and these equivalent forms also fall within the scope to which the present invention relates.

CLAIMS:

1. A crystalline basic salt of a compound of formula (I):



- 5 wherein the basic salt is selected from the group consisting of lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt and ammonium salt.
- 10 2. The crystalline basic salt of the compound of formula (I) according to claim 1, wherein the crystalline basic salt of the compound of formula (I) is a sodium salt; and each molecule of the crystalline sodium salt of the compound of formula (I) comprises the compound of formula (I) in free form and the sodium atom in a molar ratio of 1:1 or 1:2.
- 15 3. The crystalline basic salt of the compound of formula (I) according to claim 2, wherein each molecule of the crystalline sodium salt of the compound of formula (I) comprises the compound of formula (I) in free form and the sodium atom in a molar ratio of 1:2.
- 20 4. The crystalline basic salt of the compound of formula (I) according to claim 2, wherein the crystalline sodium salt of the compound of formula (I) is an anhydrate or a hydrate;
 preferably, each molecule of the crystalline sodium salt hydrate of the compound of formula (I) comprises the compound of formula (I) in free form and the water molecule in a molar ratio of 1.0:(0.1-10.0);
25 **more preferably**, each molecule of the crystalline sodium salt hydrate of the compound of formula (I) comprises the compound of formula (I) in free form and the water molecule in a molar ratio of 1.0:(1.0-5.0);
 most preferably, each molecule of the crystalline sodium salt hydrate of the compound of formula (I) comprises the compound of formula (I) in free form and the
30 water molecule in a molar ratio of 1.0:4.0 or 1.0:2.0.
- 35 5. The crystalline basic salt of the compound of formula (I) according to claim 4, wherein the crystalline basic salt of the compound of formula (I) is a crystalline form A of disodium salt hydrate having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of $8.60\pm 0.2^\circ$, $9.97\pm 0.2^\circ$, $12.92\pm 0.2^\circ$,

15.03±0.2°, 17.62±0.2°, 17.93±0.2°, 20.04±0.2°, 22.07±0.2°, 23.18±0.2°, 23.60±0.2° and 27.06±0.2°;

5 **preferably**, the X-ray powder diffraction (XRPD) pattern of the crystalline form A of disodium salt hydrate comprises peaks substantially identical to those at angles of diffraction (2θ) shown in FIG. 1.

6. The crystalline basic salt of the compound of formula (I) according to claim 5, wherein a unit cell of the crystalline form A of disodium salt hydrate is a monoclinic crystal system with the following unit cell parameters: a = 20.00(5) Å, b = 5.798(16) Å,
10 c = 20.44(11) Å, α = 90°, β = 94.8(2)°, γ = 90°, a unit cell volume V of 2362(15) Å³ and space group of C2 (No. 5).

7. The crystalline basic salt of the compound of formula (I) according to claim 4, wherein the crystalline basic salt of the compound of formula (I) is a crystalline form B
15 of disodium salt anhydrate having an X-ray powder diffraction (XRPD) pattern comprising five or more peaks at angles of diffraction (2θ) of 6.60±0.2°, 7.46±0.2°, 12.43±0.2°, 13.32±0.2°, 13.63±0.2°, 15.54±0.2°, 17.32±0.2°, 18.68±0.2° and 21.73±0.2°;

preferably, the X-ray powder diffraction (XRPD) pattern of the crystalline form B of disodium salt anhydrate comprises peaks substantially identical to those at angles of
20 diffraction (2θ) shown in FIG. 2.

8. A preparation method for the crystalline basic salt of the compound of formula (I) according to any one of claims 1-7, comprising the following steps:

1) dissolving or dispersing the compound of formula (I) in free form in water or a
25 suitable organic solvent, and adding a basic solution to the above system to conduct a salt-forming reaction; or adding the compound of formula (I) in free form to a basic solution to conduct a salt-forming reaction; and

2) collecting a solid product precipitated during the above salt-forming reaction, or
30 creating a degree of supersaturation in the salt-forming system to obtain the crystalline basic salt of the compound of formula (I);

wherein the basic salt is selected from the group consisting of lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt and ammonium salt; and

the basic solution is selected from the group consisting of solutions of lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium
35 hydroxide and ammonia in water or in an organic solvent.


9. The preparation method according to claim 8, wherein methods for creating the degree of supersaturation in the salt-forming system in step 2) include one or more of the following: adding a seed crystal, volatilizing the solvent, adding an anti-solvent and
40 cooling.

10. The preparation method according to claim 8, wherein the organic solvent is selected from the group consisting of alcohols, chloroalkanes, ketones, ethers, cyclic ethers, esters, alkanes, cycloalkanes, benzenes, amides and sulfoxides, and mixtures thereof and aqueous solutions thereof;

preferably, the organic solvent is selected from the group consisting of methanol, ethanol, *n*-propanol, isopropanol, dichloromethane, heptane, acetonitrile, acetone, methyl ethyl ketone, toluene, 1,4-dioxane, tetrahydrofuran, *N,N*-dimethylformamide, ethyl acetate, isopropyl acetate, methyl *tert*-butyl ether and 2-methoxyethyl ether, and mixtures thereof and aqueous solutions thereof.

11. A preparation method for the crystalline basic salt of the compound of formula (I) according to any one of claims 1-7, comprising the following step: transforming one crystalline form of the basic salt of the compound of formula (I) into another crystalline form of the salt by using a crystalline form transformation method, wherein the crystalline form transformation method includes heating or suspension crystalline form transformation in a solvent selected from the group consisting of methanol, ethanol, *n*-propanol, isopropanol, dichloromethane, heptane, acetonitrile, acetone, methyl ethyl ketone, toluene, 1,4-dioxane, tetrahydrofuran, *N,N*-dimethylformamide, ethyl acetate, isopropyl acetate, methyl *tert*-butyl ether and 2-methoxyethyl ether, and mixtures thereof and aqueous solutions thereof.

12. A crystalline form of a compound of formula (I) in free form:



preferably, the crystalline form of the compound of formula (I) in free form is crystalline form C, crystalline form D, crystalline form E or crystalline form F.

13. The crystalline form of the compound of formula (I) in free form according to claim 12, wherein the crystalline form of the compound of formula (I) in free form is the crystalline form C, an X-ray powder diffraction (XRPD) pattern of which comprises five or more peaks at angles of diffraction (2θ) of $7.80\pm 0.2^\circ$, $11.97\pm 0.2^\circ$, $12.42\pm 0.2^\circ$, $15.98\pm 0.2^\circ$, $17.37\pm 0.2^\circ$, $18.82\pm 0.2^\circ$, $22.47\pm 0.2^\circ$, $23.30\pm 0.2^\circ$, $25.01\pm 0.2^\circ$ and $25.63\pm 0.2^\circ$;

preferably, the X-ray powder diffraction (XRPD) pattern of the crystalline form C comprises peaks substantially identical to those at angles of diffraction (2θ) shown in FIG.

3.

14. The crystalline form of the compound of formula (I) in free form according to claim 12, wherein the crystalline form of the compound of formula (I) in free form is the crystalline form D, an X-ray powder diffraction (XRPD) pattern of which comprises five or more peaks at angles of diffraction (2θ) of $7.97\pm0.2^\circ$, $11.82\pm0.2^\circ$, $12.18\pm0.2^\circ$,
5 $14.87\pm0.2^\circ$, $16.13\pm0.2^\circ$, $17.18\pm0.2^\circ$, $19.21\pm0.2^\circ$, $20.72\pm0.2^\circ$ and $25.28\pm0.2^\circ$;

preferably, the X-ray powder diffraction (XRPD) pattern of the crystalline form D comprises peaks substantially identical to those at angles of diffraction (2θ) shown in FIG. 4.

10 15. The crystalline form of the compound of formula (I) in free form according to claim 12, wherein the crystalline form of the compound of formula (I) in free form is the crystalline form E, an X-ray powder diffraction (XRPD) pattern of which comprises five or more peaks at angles of diffraction (2θ) of $8.16\pm0.2^\circ$, $12.05\pm0.2^\circ$, $12.83\pm0.2^\circ$,
15 $15.19\pm0.2^\circ$, $16.18\pm0.2^\circ$, $16.59\pm0.2^\circ$, $17.62\pm0.2^\circ$, $18.41\pm0.2^\circ$, $22.90\pm0.2^\circ$ and $25.65\pm0.2^\circ$;

preferably, the X-ray powder diffraction (XRPD) pattern of the crystalline form E comprises peaks substantially identical to those at angles of diffraction (2θ) shown in FIG. 5.

20 16. The crystalline form of the compound of formula (I) in free form according to claim 12, wherein the crystalline form of the compound of formula (I) in free form is the crystalline form F, an X-ray powder diffraction (XRPD) pattern of which comprises five or more peaks at angles of diffraction (2θ) of $6.92\pm0.2^\circ$, $9.10\pm0.2^\circ$, $12.42\pm0.2^\circ$,
25 $13.46\pm0.2^\circ$, $14.38\pm0.2^\circ$, $15.84\pm0.2^\circ$, $19.04\pm0.2^\circ$, $22.00\pm0.2^\circ$ and $26.23\pm0.2^\circ$;

preferably, the X-ray powder diffraction (XRPD) pattern of the crystalline form F comprises peaks substantially identical to those at angles of diffraction (2θ) shown in FIG. 6.

30 17. Use of the crystalline form of the compound of formula (I) in free form according to any one of claims 12-16, wherein the crystalline form of the compound of formula (I) in free form is used as a starting material to prepare the crystalline basic salt of the compound of formula (I) according to any one of claims 1-7.

35 18. A pharmaceutical composition, comprising a clinically effective amount of the crystalline basic salt of the compound of formula (I) according to any one of claims 1-7 or the crystalline form of the compound of formula (I) in free form according to any one of claims 12-16 and a pharmaceutically acceptable carrier;

preferably, the pharmaceutical composition comprises 0.01-99.0% W/W of the crystalline basic salt of the compound of formula (I) or the crystalline form of the compound of formula (I) in free form relative to a total content of the pharmaceutical
40 composition.

19. Use of the crystalline basic salt of the compound of formula (I) according to any one of claims 1-7 or the crystalline form of the compound of formula (I) in free form according to any one of claims 12-16 in preparation of a medicament for treating a PD-1/PD-L1 signal pathway-mediated tumor, immunity-related disease and disorder, communicable disease, infectious disease or metabolic disease;

preferably, the tumor is cancer.

20. The use according to claim 19, wherein the infectious disease is a bacterial infectious disease, a viral infectious disease or a fungal infectious disease.

21. The use according to claim 19, wherein the tumor is lymphoma, sarcoma, melanoma, glioblastoma, synovioma, meningioma, biliary tract tumor, neuroma, seminoma, nephroblastoma, hepatocellular papilloma, papilloma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, lipoma, fibroma, central nervous system tumor, spinal axis tumor, brain stem glioma, multiple myeloma, ovarian tumor, myelodysplastic syndrome or mesothelioma, anal cancer, testicular cancer, urethral carcinoma, penile cancer, bladder cancer, ureteral cancer, uterine cancer, ovarian cancer, fallopian tube cancer, cervical cancer, vaginal cancer, vulvar cancer, Merkel cell carcinoma, embryonal carcinoma, chronic or acute leukemia, bronchial carcinoma, esophageal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, basal cell carcinoma, lung cancer, adenocarcinoma, papillary carcinoma, rectal cancer, colon cancer, gastric cancer, head and neck cancer, bone cancer, skin cancer, small intestine cancer, endocrine cancer, renal pelvic carcinoma, epidermoid carcinoma, transitional cell carcinoma or choriocarcinoma;

the immunity-related disease and disorder is rheumatic arthritis, renal failure, lupus erythematosus, asthma, psoriasis, ulcerative colitis, pancreatitis, allergy, fibrosis, anemia, fibromyalgia, Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, Crohn's disease, ulcerative colitis, allergic contact dermatitis and eczema, systemic sclerosis or multiple sclerosis;

the communicable disease or infectious disease is sepsis, liver infection, hepatitis A, hepatitis B, hepatitis C, hepatitis D, herpes virus, papillomavirus or influenza; and

the metabolic disease is diabetes, diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, hypoglycemia, gout, malnutrition, vitamin A deficiency, scurvy, vitamin D deficiency or osteoporosis.

22. The use according to claim 21, wherein the lymphoma is lymphocytic lymphoma, primary central nervous system lymphoma, T cell lymphoma, diffuse large B cell lymphoma, follicle center lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma or primary mediastinal large B cell lymphoma;

the sarcoma is Kaposi's sarcoma, fibrosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, leiomyosarcoma, rhabdomyosarcoma, soft tissue sarcoma, angiosarcoma or lymphangiosarcoma; and

5 the chronic or acute leukemia is acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic granulocytic leukemia or chronic lymphoblastic leukemia.

23. The use according to claim 19, wherein the tumor is small cell lung cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer,
10 chondroma, colorectal cancer, gastrointestinal cancer, endometrial cancer, head and neck squamous cell carcinoma, abdominal wall carcinoma, renal cell carcinoma or recurrent or existing drug-resistant prostate cancer.

24. The use according to claim 19, wherein the tumor is thymic tumor, pleomorphic
15 adenoma, renal tubule adenoma, cystadenoma, pituitary adenoma, prostate cancer, thyroid cancer, parathyroid cancer, adrenal cancer, breast cancer, cystadenocarcinoma or pancreatic cancer.

25. The crystalline basic salt of the compound of formula (I) according to any one
20 of claims 1-7 or the crystalline form of the compound of formula (I) in free form according to any one of claims 12-16 for use as a medicament for treating a PD-1/PD-L1 signal pathway-mediated tumor, immunity-related disease and disorder, communicable disease, infectious disease or metabolic disease.